Therapy Detail

Therapy Name Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine
Synonym Rituximab + CHOP
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Doxorubicin Adriamycin Adria|ADR Chemotherapy - Anthracycline 11 TOPO2 inhibitor 4 Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).
Prednisone Adasone Dehydrocortisone Prednisone is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).
Rituximab Rituxan IDEC-C2B8 CD20 Antibody 3 Rituxan (rituximab) is a chimeric mononclonal CD20-targeted antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent cytotoxicity and antibody-dependent cellular cytoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia (FDA.gov).
Vincristine Oncovin 22-Oxovincaleukoblastine Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03467373 Phase I Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine RO7082859 Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + RO7082859 + Vincristine Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + RO7082859 + Vincristine A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas Recruiting
NCT03671018 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Cyclophosphamide + Prednisone + Rituximab + Vincristine Bendamustine + Polatuzumab Vedotin + Rituximab Bendamustine + Obinutuzumab BTCT4465A + Polatuzumab Vedotin BTCT4465A Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Recruiting
NCT03263026 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Enzastaurin Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 Recruiting
NCT03274492 Phase III Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03505762 Phase II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment Recruiting
NCT02605694 Phase II Duvelisib + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Withdrawn
NCT03742258 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TAK-659 + Vincristine Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Recruiting
NCT01334502 Phase I Everolimus Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma Completed